低氧诱导因子脯氨酰羟化酶抑制剂治疗未接受透析的慢性肾脏病患者贫血的心脏与肾脏不良效应:系统评价与荟萃分析
该系统评价与荟萃分析纳入23项随机对照试验共15144例未接受维持透析的慢性肾脏病贫血患者,比较低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHIs)与安慰剂或红细胞生成刺激剂(ESA)的心脏及肾脏相关不良事件风险。结果显示HIF-PHIs组与安慰剂或ESA组的心脏及肾脏相关不良事件风险均无显著差异,但HIF-PHIs组高血压和高钾血症发生风险高于安慰剂组,高血压发生风险低于ESA组。
要点
- HIF-PHIs与安慰剂或ESA相比,心脏及肾脏相关不良事件风险无显著差异。
- HIF-PHIs组高血压(RR 1.35)和高钾血症(RR 1.25)风险高于安慰剂组,证据确定性高。
- HIF-PHIs组高血压风险低于ESA组(RR 0.89),证据确定性中等。
核心结论
- HIF-PHIs组的心脏或肾脏相关不良事件发生率与安慰剂组或ESA组相比无差异。
研究设计与样本
- 系统评价与荟萃分析,纳入23项随机对照试验,共15144例未接受维持透析的慢性肾脏病贫血患者。
- 比较HIF-PHIs与安慰剂或ESA,主要结局为心脏和肾脏相关不良事件。
- 采用Mantel-Haenszel法合并二分类变量,以风险比(RR)表示,并按GRADE标准评级证据确定性。
主要发现
- 心脏不良事件风险:HIF-PHIs组与安慰剂组相比无显著差异(RR 1.02,95%CI 0.89-1.16;中等确定性);与ESA组相比无显著差异(RR 1.06,95%CI 0.98-1.14;低确定性)。
- 肾脏相关不良事件风险:HIF-PHIs组与安慰剂组相比无显著差异(RR 1.09,95%CI 0.98-1.20;中等确定性);与ESA组相比无显著差异(RR 1.00,95%CI 0.94-1.06;低确定性)。
- 高血压发生风险:HIF-PHIs组高于安慰剂组(RR 1.35,95%CI 1.14-1.60;高确定性);HIF-PHIs组低于ESA组(RR 0.89,95%CI 0.81-0.98;中等确定性)。
- 高钾血症发生风险:HIF-PHIs组高于安慰剂组(RR 1.25,95%CI 1.03-1.51;高确定性)。
局限性
- 各试验间心脏和肾脏相关不良事件的报告标准及HIF-PHIs剂量不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are novel, orally administered agents for anemia management in chronic kidney disease (CKD). We evaluated the cardiac and kidney-related adverse effects of HIF-PHIs among patients with CKD and anemia. STUDY DESIGN: Systematic review and meta-analysis of randomized controlled trials (RCTs). SETTING & STUDY POPULATIONS: Patients with anemia and CKD not receiving maintenance dialysis. SELECTION CRITERIA FOR STUDIES: RCTs comparing HIF-PHIs to placebo or an erythropoiesis-stimulating agent (ESA) with primary outcomes of cardiac and kidney-related adverse events (AEs). DATA EXTRACTION: Two independent reviewers evaluated RCTs for eligibility and extracted relevant data. ANALYTICAL APPROACH: Dichotomous variables were pooled using the Mantel-Haenszel method and presented as risk ratios (RRs). Subgroup analyses evaluated different intervention times and HIF-PHIs, as well as phase 2 versus phase 3 trials. The certainty of findings was rated according to GRADE criteria. RESULTS: Twenty-three studies with 15,144 participants were included. No significant difference in the risk of cardiac AEs was observed between the HIF-PHIs group and the placebo (RR, 1.02 [95% CI, 0.89-1.16]; moderate certainty) or ESA (RR, 1.06 [95% CI, 0.98-1.14]; low certainty) groups. No significant difference in the risk of kidney-related AEs was observed between the HIF-PHIs group and the placebo (RR, 1.09 [95% CI, 0.98-1.20]; moderate certainty) or ESA (RR, 1.00 [95% CI, 0.94-1.06]; low certainty) groups. The occurrence of hypertension and hyperkalemia was higher in the HIF-PHIs group than in the placebo group (RRs of 1.35 [95% CI, 1.14-1.60] and 1.25 [95% CI, 1.03-1.51], respectively; both findings had high certainty). The occurrence of hypertension was lower in the HIF-PHIs group than in the ESA group (RR, 0.89 [95% CI, 0.81-0.98]; moderate certainty). LIMITATIONS: The reporting criteria of cardiac and kidney-related AEs and dosage of HIF-PHIs were inconsistent across trials. CONCLUSIONS: The occurrence of cardiac or kidney-related AEs in the HIF-PHI groups were not different compared with placebo or ESA groups. REGISTRATION: Registered at PROSPERO with registration number CRD42021228243.
引用
- Zheng Q, Wang Y, Yang H, et al. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2022. PMID: 36396085. doi:10.1053/j.ajkd.2022.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。